Read by QxMD icon Read

Doi yohei

Yohei Komaru, Kent Doi
No abstract text is available yet for this article.
September 2016: Journal of Thoracic Disease
Belén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, Po-Ren Hsueh, Pierluigi Viale, José Ramón Paño-Pardo, Mario Venditti, Mario Tumbarello, George Daikos, Vicente Pintado, Yohei Doi, Felipe Francisco Tuon, Ilias Karaiskos, Isabel Machuca, Mitchell J Schwaber, Özlem Kurt Azap, Maria Souli, Emmanuel Roilides, Spyros Pournaras, Murat Akova, Federico Pérez, Joaquín Bermejo, Antonio Oliver, Manel Almela, Warren Lowman, Benito Almirante, Robert A Bonomo, Yehuda Carmeli, David L Paterson, Alvaro Pascual, Jesús Rodríguez-Baño
OBJECTIVE: To develop a score to predict mortality in patients with bloodstream infections (BSIs) due to carbapenemase-producing Enterobacteriaceae (CPE). PATIENTS AND METHODS: A multinational retrospective cohort study (INCREMENT project) was performed from January 1, 2004, through December 31, 2013. Patients with clinically relevant monomicrobial BSIs due to CPE were included and randomly assigned to either a derivation cohort (DC) or a validation cohort (VC)...
October 2016: Mayo Clinic Proceedings
Tolani F Olonisakin, Huihua Li, Zeyu Xiong, Elizabeth J K Kochman, Minting Yu, Yanyan Qu, Mei Hulver, Jay K Kolls, Claudette St Croix, Yohei Doi, Minh-Hong Nguyen, Robert M Q Shanks, Rama K Mallampalli, Valerian E Kagan, Anuradha Ray, Roy L Silverstein, Prabir Ray, Janet S Lee
Klebsiella pneumoniae remains an important cause of intrapulmonary infection and invasive disease worldwide. Klebsiella pneumoniae can evade serum killing and phagocytosis primarily through the expression of a polysaccharide capsule, but its pathogenicity is also influenced by host factors. We examined whether CD36, a scavenger receptor that recognizes pathogen and modified-self ligands, is a host determinant of Klebsiella pneumoniae pathogenicity. Despite differences in serum sensitivity and virulence of three distinct Klebsiella pneumoniae (hypermucoviscous K1, research K2, carbapenemase-producing ST258) strains utilized, the absence of CD36 significantly increased host susceptibility to acute intrapulmonary infection by K...
September 28, 2016: Journal of Infectious Diseases
Masahiro Shimamura, Jun Miyakawa, Masaaki Doi, Kiyonobu Okada, Hajimu Kurumatani, Yoshitaka Mori, Keiyu Oshida, Ikumi Nakajo, Keishi Oikawa, Fumihiko Ushigome, Aiji Miyashita, Masanao Isono, Yohei Miyamoto
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS-314d, in Japanese subjects with impaired kidney function. The plasma and urine concentrations of BPS and BPS-314d were measured following the single oral administration of 120 μg of BPS as the sustained-release tablet, TRK-100STP, under fasting conditions to 18 subjects with impaired kidney function (stage 2, 3, and 4 chronic kidney disease (CKD) (as categorized by the estimated glomerular filtration rate)) and to 6 age-, body weight-, and gender-matched subjects with normal kidney function (stage 1 CKD)...
September 28, 2016: Journal of Clinical Pharmacology
Peng Wang, Sarah L Bowler, Serena F Kantz, Roberta T Mettus, Yan Guo, Christi L McElheny, Yohei Doi
Treatment options for infections due to carbapenem-resistant Acinetobacter baumannii are extremely limited. Minocycline is a semisynthetic tetracycline derivative with activity against this pathogen. This study compared susceptibility testing methods that are conducted in clinical microbiology laboratories (Etest, disk diffusion, Sensititre broth microdilution [BMD]) for minocycline, tigecycline and doxycycline against 107 carbapenem-resistant A. baumannii clinical isolates. Susceptibility rates with the standard BMD method using cation-adjusted Mueller-Hinton (MH) broth were 77...
September 14, 2016: Journal of Clinical Microbiology
Elena K Schneider, Mohammad A K Azad, Mei-Ling Han, Qi Tony Zhou, Jiping Wang, Johnny X Huang, Matthew A Cooper, Yohei Doi, Mark A Baker, Phillip J Bergen, Mark T Muller, Jian Li, Tony Velkov
Novel combination therapies are desperately needed for combating lung infections caused by bacterial "superbugs". This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with the cystic fibrosis (CF) drugs KALYDECO (ivacaftor) and ORKAMBI (ivacaftor + lumacaftor) against Gram-negative pathogens that commonly colonize the CF lung, in particular, the problematic Pseudomonas aeruginosa. The in vitro synergistic activity of polymyxin B combined with ivacaftor or lumacaftor was assessed using checkerboard and static time-kill assays against a panel of polymyxin-susceptible and polymyxin-resistant P...
July 8, 2016: ACS Infectious Diseases
Ryan K Shields, Brian A Potoski, Ghady Haidar, Binghua Hao, Yohei Doi, Liang Chen, Ellen G Press, Barry N Kreiswirth, Cornelius J Clancy, M Hong Nguyen
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30-days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90-days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
September 13, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
David van Duin, Yohei Doi
Carbapenemase-producing Enterobacteriaceae (CPE) are an important and increasing threat to global health. Both clonal spread and plasmid-mediated transmission contribute to the ongoing rise in incidence of these bacteria. Among the 4 classes of β-lactamases defined by the Ambler classification system, the carbapenemases that confer carbapenem resistance in Enterobacteriaceae belong to 3 of them: Class A (K. pneumoniae carbapenemases, KPC), Class B (metallo-β-lactamases, MBL including New Delhi metallo-β-lactamases, NDM) and Class D (OXA-48-like carbapenemases)...
August 11, 2016: Virulence
Qinglan Guo, Baixing Ding, Thomas Jové, Nicole Stoesser, Vaughn S Cooper, Minggui Wang, Yohei Doi
Extended-spectrum β-lactamase gene blaCTX-M-2 is mainly associated with ISCR1 embedded in complex sul1-type integrons, but information on the genetic context of plasmids harboring the ISCR1-blaCTX-M-2module remains limited. In this study, a blaCTX-M-2-harboring plasmid pYD786-1 belonging to novel ST2-IncHI2 was sequenced and analyzed from an Escherichia coli ST410 clinical strain. pYD786-1 belonged to APEC-O1-R type IncHI2 plasmids which are widely distributed in human, poultry and livestock strains. It contained a multidrug resistance mosaic region (MRR) consisting of Tn21::In2 transposon backbone augmented by acquisition of duplicated ISCR1-blaCTX-M-2 Tn2411, a Tn21::In2 precursor, likely played a role in the generation of the MRR in pN13-01290_23, the putative progenitor plasmid of pYD786-1 found in a foodborne Salmonella strain...
August 29, 2016: Antimicrobial Agents and Chemotherapy
Ghady Haidar, Ammar Alkroud, Shaoji Cheng, Travis M Churilla, Bryce M Churilla, Ryan K Shields, Yohei Doi, Cornelius J Clancy, M Hong Nguyen
We compared the in vitro activities of gentamicin (GEN), tobramycin (TOB), amikacin (AMK), and plazomicin (PLZ) against 13 Enterobacter isolates possessing both Klebsiella pneumoniae carbapenemase and extended-spectrum β-lactamase (KPC+/ESBL+) with activity against 8 KPC+/ESBL-, 6 KPC-/ESBL+, and 38 KPC-/ESBL- isolates. The rates of resistance to GEN and TOB were higher for KPC+/ESBL+ (100% for both) than for KPC+/ESBL- (25% and 38%, respectively), KPC-/ESBL+ (50% and 17%, respectively), and KPC-/ESBL- (0% and 3%, respectively) isolates...
September 2016: Antimicrobial Agents and Chemotherapy
Sarah L Bowler, Caressa N Spychala, Christi L McElheny, Roberta T Mettus, Yohei Doi
No abstract text is available yet for this article.
August 2016: Antimicrobial Agents and Chemotherapy
Qinglan Guo, Adam D Tomich, Christi L McElheny, Vaughn S Cooper, Nicole Stoesser, Minggui Wang, Nicolas Sluis-Cremer, Yohei Doi
OBJECTIVES: The objectives of this study were to elucidate the genetic context of a novel plasmid-mediated fosA variant, fosA6, conferring fosfomycin resistance and to characterize the kinetic properties of FosA6. METHODS: The genome of fosfomycin-resistant Escherichia coli strain YD786 was sequenced. Homologues of FosA6 were identified through BLAST searches. FosA6 and FosA(ST258) were purified and characterized using a steady-state kinetic approach. Inhibition of FosA activity was examined with sodium phosphonoformate...
September 2016: Journal of Antimicrobial Chemotherapy
Toshiaki Ohkuma, Udai Nakamura, Masanori Iwase, Hitoshi Ide, Hiroki Fujii, Tamaki Jodai, Shinako Kaizu, Yohei Kikuchi, Yasuhiro Idewaki, Akiko Sumi, Yoichiro Hirakawa, Takanari Kitazono
Cigarette smoking is an important modifiable risk factor for lifestyle diseases. The smoking rate remains high, and the prevalence of diabetes mellitus is increasing in Asian countries; however, few studies have examined the effects of smoking on chronic kidney disease (CKD) in Asian diabetic patients. The aim of the present study was to investigate the association between smoking and its cessation with CKD and its components in patients with type 2 diabetes. A total of 2770 Japanese male patients with type 2 diabetes aged ⩾20 years were divided according to the amount of cigarette smoking and the years since cessation...
June 2, 2016: Hypertension Research: Official Journal of the Japanese Society of Hypertension
Yohei Doi, Jun-Ichi Wachino, Yoshichika Arakawa
Aminoglycoside-producing Actinobacteria are known to protect themselves from their own aminoglycoside metabolites by producing 16S ribosomal RNA methyltransferase (16S-RMTase), which prevents them from binding to the 16S rRNA targets. Ten acquired 16S-RMTases have been reported from gram-negative pathogens. Most of them posttranscriptionally methylate residue G1405 of 16S rRNA resulting in high-level resistance to gentamicin, tobramycin, amikacin, and plazomicin. Strains that produce 16S-RMTase are frequently multidrug-resistant or even extensively drug-resistant...
June 2016: Infectious Disease Clinics of North America
Luis A Shimose, Eriko Masuda, Maroun Sfeir, Ana Berbel Caban, Maria X Bueno, Dennise dePascale, Caressa N Spychala, Timothy Cleary, Nicholas Namias, Daniel H Kett, Yohei Doi, L Silvia Munoz-Price
OBJECTIVE To concomitantly determine the differential degrees of air and environmental contamination by Acinetobacter baumannii based on anatomic source of colonization and type of ICU layout (single-occupancy vs open layout). DESIGN Longitudinal prospective surveillance study of air and environmental surfaces in patient rooms. SETTING A 1,500-bed public teaching hospital in Miami, Florida. PATIENTS Consecutive A. baumannii-colonized patients admitted to our ICUs between October 2013 and February 2014. METHODS Air and environmental surfaces of the rooms of A...
July 2016: Infection Control and Hospital Epidemiology
Shinichiro Tomitaka, Yohei Kawasaki, Kazuki Ide, Hiroshi Yamada, Hirotsugu Miyake, Toshiaki A Furukawa
No abstract text is available yet for this article.
2016: PloS One
Kun-Jiao Zeng, Yohei Doi, Sandip Patil, Xi Huang, Guo-Bao Tian
No abstract text is available yet for this article.
June 2016: Antimicrobial Agents and Chemotherapy
Sangeeta Sastry, Yohei Doi
Fosfomycin was discovered over four decades ago, yet has drawn renewed interest as an agent active against a range of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens. Its unique mechanism of action and broad spectrum of activity makes it a promising candidate in the treatment of various MDR/XDR infections. There has been a surge of in vitro data on its activity against MDR/XDR organisms, both when used as a single agent and in combination with other agents. In the United States, fosfomycin is only approved in an oral formulation for the treatment of acute uncomplicated urinary tract infections (UTIs), whereas in some countries both oral and intravenous formulations are available for various indications...
May 2016: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
Shoko Doi, Yohei Ohno, Gaku Nakazawa, Yuji Ikari
No abstract text is available yet for this article.
September 7, 2016: European Heart Journal
C Hauck, E Cober, S S Richter, F Perez, R A Salata, R C Kalayjian, R R Watkins, N M Scalera, Y Doi, K S Kaye, S Evans, V G Fowler, R A Bonomo, D van Duin
Patients infected or colonized with carbapenem-resistant Klebsiella pneumoniae (CRKp) are often chronically and acutely ill, which results in substantial mortality unrelated to infection. Therefore, estimating excess mortality due to CRKp infections is challenging. The Consortium on Resistance against Carbapenems in K. pneumoniae (CRACKLE) is a prospective multicenter study. Here, patients in CRACKLE were evaluated at the time of their first CRKp bloodstream infection (BSI), pneumonia or urinary tract infection (UTI)...
June 2016: Clinical Microbiology and Infection
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"